We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Walmart, Honeywell, Zoetis, Colgate-Palmolive and IDEXX Lab
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 1, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Walmart Inc. (WMT - Free Report) , Honeywell International Inc. (HON - Free Report) , Zoetis Inc. (ZTS - Free Report) , Colgate-Palmolive Company (CL - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Walmart, Honeywell and Zoetis
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart, Honeywell, and Zoetis. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Walmart have lagged the broader market this year (up +3.5% in the year-to-date period vs. +26.5% gain for the S&P 500 index) as the market sees the company vulnerable to ongoing supply-chain issues. The Zacks analyst has a favorable outlook for the company and sees the company continuing to gain ground on the back of its omnichannel efforts.
In order to boost e-commerce sales, the company is strengthening its delivery capabilities. This, along with efforts to enhance store experience, fueled second-quarter results. Walmart also raised its fiscal 2022 guidance on the back of robust underlying market trends. The company, however, has been encountering high costs related to the ongoing pandemic, as well as increased wage expense.
Honeywell shares have gained +7.5% in the year to date period against the Zacks Diversified Operations industry’s gain of +15.8%. It has been dealing with high costs as well as supply chain challenges, which might stress its margins. Weakness in the defense and space businesses are likely to adversely impact its near-term results.
The Zacks analyst, however, believes that the company is poised to benefit from strength in the warehouse and workflow solutions business, along with recovery in the commercial aviation business in the quarters ahead. Operational excellence initiatives, acquisitions, and strong cash flow are likely to further drive Honeywell's competency.
Shares of Zoetis have gained +34.8% over the past year against the Zacks Drugs industry’s loss of -14.3%. The Zacks analyst believes that a diversified product portfolio, global footprint and productive R&D should keep driving both top-and bottom-line growth.
Its third quarter results were driven by strong performances from its portfolio of petcare parasiticides, including Simparica Trio, as well as dermatology products. The uptake of Librela and Solensia, its new monoclonal antibody therapies for osteoarthritis pain in dogs and cats is another major positive. Development and regulatory setbacks for late-stage pipeline candidates and stiff competition in the animal health space remain major threats to the company though.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Walmart, Honeywell, Zoetis, Colgate-Palmolive and IDEXX Lab
For Immediate Release
Chicago, IL – November 1, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Walmart Inc. (WMT - Free Report) , Honeywell International Inc. (HON - Free Report) , Zoetis Inc. (ZTS - Free Report) , Colgate-Palmolive Company (CL - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Walmart, Honeywell and Zoetis
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart, Honeywell, and Zoetis. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Walmart have lagged the broader market this year (up +3.5% in the year-to-date period vs. +26.5% gain for the S&P 500 index) as the market sees the company vulnerable to ongoing supply-chain issues. The Zacks analyst has a favorable outlook for the company and sees the company continuing to gain ground on the back of its omnichannel efforts.
In order to boost e-commerce sales, the company is strengthening its delivery capabilities. This, along with efforts to enhance store experience, fueled second-quarter results. Walmart also raised its fiscal 2022 guidance on the back of robust underlying market trends. The company, however, has been encountering high costs related to the ongoing pandemic, as well as increased wage expense.
(You can read the full research report on Walmart here >>>)
Honeywell shares have gained +7.5% in the year to date period against the Zacks Diversified Operations industry’s gain of +15.8%. It has been dealing with high costs as well as supply chain challenges, which might stress its margins. Weakness in the defense and space businesses are likely to adversely impact its near-term results.
The Zacks analyst, however, believes that the company is poised to benefit from strength in the warehouse and workflow solutions business, along with recovery in the commercial aviation business in the quarters ahead. Operational excellence initiatives, acquisitions, and strong cash flow are likely to further drive Honeywell's competency.
(You can read the full research report on Honeywell here >>>)
Shares of Zoetis have gained +34.8% over the past year against the Zacks Drugs industry’s loss of -14.3%. The Zacks analyst believes that a diversified product portfolio, global footprint and productive R&D should keep driving both top-and bottom-line growth.
Its third quarter results were driven by strong performances from its portfolio of petcare parasiticides, including Simparica Trio, as well as dermatology products. The uptake of Librela and Solensia, its new monoclonal antibody therapies for osteoarthritis pain in dogs and cats is another major positive. Development and regulatory setbacks for late-stage pipeline candidates and stiff competition in the animal health space remain major threats to the company though.
(You can read the full research report on Zoetis here >>>)
Other noteworthy reports we are featuring today include Colgate-Palmolive Company and IDEXX Laboratories.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.